TY - JOUR
T1 - 68 Ga-PSMA PET/CT staging of newly diagnosed intermediate- and high-risk prostate cancer
AU - Kuten, Jonathan
AU - Mabjeesh, Nicola J.
AU - Lerman, Hedva
AU - Levine, Charles
AU - Barnes, Sophie
AU - Even-Sapir, Einat
N1 - Publisher Copyright:
© 2019, Israel Medical Association Journal, All rights reserved.
PY - 2019/2
Y1 - 2019/2
N2 - Background: 68 Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography ( 68 Ga-PSMA PET/CT) is part of the initial workup of patients with intermediate and high-risk prostate cancer provided by the Israeli national health services. Objectives: To assess the incidence of metastatic spread in consecutive patients with newly diagnosed cancer, and the potential added value of 68 Ga-PSMA PET/CT to the staging imaging algorithm. Methods: Patients with newly diagnosed intermediate- and high-risk prostate cancer were referred for initial staging by 68 Ga- PSMA PET/CT between May 2016 and April 2017. Blood prostatespecific antigen (PSA) levels, clinical history, imaging reports and histopathological reports (including Gleason scores) were obtained. Maximal standardized uptake values (SUVmax) were determined for the primary lesions detected within the prostate. Results: The study included 137 consecutive patients with intermediate- and high-risk disease who underwent 68 Ga- PSMA PET/CT staging. Of these, 75 had 68 Ga-PSMA uptake in both prostate lobes, 57 had unilateral uptake, and 5 patients had no uptake. SUVmax in the primary tumor correlated significantly with PSA levels. Thirty-five patients had increased uptake compatible with metastatic disease involving lymph nodes, bone, and viscera. Twenty-seven patients had available bone scintigraphy results: 18 (69%) of their 26 bone metastases detected by 68 Ga-PSMA PET/CT were missed on bone scintigraphy. Conclusions: 68 Ga-PSMA PET/CT shows promise as a sole wholebody imaging modality for assessing the presence of soft tissue and bone metastases in the setting of prostate cancer.
AB - Background: 68 Ga-prostate-specific membrane antigen positron emission tomography/computerized tomography ( 68 Ga-PSMA PET/CT) is part of the initial workup of patients with intermediate and high-risk prostate cancer provided by the Israeli national health services. Objectives: To assess the incidence of metastatic spread in consecutive patients with newly diagnosed cancer, and the potential added value of 68 Ga-PSMA PET/CT to the staging imaging algorithm. Methods: Patients with newly diagnosed intermediate- and high-risk prostate cancer were referred for initial staging by 68 Ga- PSMA PET/CT between May 2016 and April 2017. Blood prostatespecific antigen (PSA) levels, clinical history, imaging reports and histopathological reports (including Gleason scores) were obtained. Maximal standardized uptake values (SUVmax) were determined for the primary lesions detected within the prostate. Results: The study included 137 consecutive patients with intermediate- and high-risk disease who underwent 68 Ga- PSMA PET/CT staging. Of these, 75 had 68 Ga-PSMA uptake in both prostate lobes, 57 had unilateral uptake, and 5 patients had no uptake. SUVmax in the primary tumor correlated significantly with PSA levels. Thirty-five patients had increased uptake compatible with metastatic disease involving lymph nodes, bone, and viscera. Twenty-seven patients had available bone scintigraphy results: 18 (69%) of their 26 bone metastases detected by 68 Ga-PSMA PET/CT were missed on bone scintigraphy. Conclusions: 68 Ga-PSMA PET/CT shows promise as a sole wholebody imaging modality for assessing the presence of soft tissue and bone metastases in the setting of prostate cancer.
KW - Ga-prostatespecific membrane antigen (PSMA)
KW - Positron emission tomography/CT (PET/CT)
KW - Prostate cancer
KW - Prostate-specific antigen (PSA)
UR - http://www.scopus.com/inward/record.url?scp=85061717299&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30772960
AN - SCOPUS:85061717299
SN - 1565-1088
VL - 21
SP - 100
EP - 104
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 2
ER -